Jason Brayer MD PhD

PubMed

• Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.
  Mark B Meads, Xiaohong Zhao, David R Noyes, Praneeth Sudalagunta, Alexandra Achille
  Blood. 2025-09-22
• Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma.
  Rafael Renatino Canevarolo, Praneeth Reddy Sudalagunta, Mark B Meads, Maria Silva, Xiaohong Zhao
  Research Square. 2025-04-15
• 1 citations
  The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma.
  Praneeth Reddy Sudalagunta, Rafael R Canevarolo, Mark B Meads, Maria Silva, Xiaohong Zhao
  Cancer Research. 2025-01-15

Abstracts/Posters

• Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma
  Jason B. Brayer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Composition of Immune Subpopulations Influence Multiple Myeloma Disease Progression
  Jason B. Brayer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis...
  Jason B. Brayer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
  Jason B. Brayer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018